To beat cancer
we need to think like cancer
Seeking breakthrough therapies that open up areas of unmet need
We have a scalable platform that can advance multiple clinical trials
By speeding up drug development we can get successful products into patients quicker
Ellipses was created to accelerate cancer treatment discoveries. We do this by ensuring more resource goes into potential drugs as soon as it is required, so that patients receive the benefit earlier
Our tumour-agnostic approach develops targeted treatments for any cancer type, giving patients the options they need
We develop drugs with any validated mechanism of action or platform to address an unlimited number of cancer types
By being open to develop any molecule for cancer, we increase opportunities for success for patients and partners
We have uninterrupted development capital for each asset that allows us to speed up pre-clinical and clinical development of partnered assets
We are custodians of the potential treatment from the acquisition stage, through clinical trials to out-license
We uncover exceptional treatments, typically at the pre-clinical to Phase 1 stage, from academia, biotech & pharma partners
We review exciting drugs with promising science, high quality data and the potential to positively impact patients and use our Scientific Affairs Group to support selection
We actively assess the market to ensure in-licensed treatments are developed to accompany existing standards of care
Successfully developed drugs are out-licensed at the appropriate point to maximise benefit to patients and partners
We are at the forefront of innovative clinical studies, using multiple different types of novel trials to optimise success
We understand the tumour types that will respond to the drug that we want to trial
Patient selection results in smaller, more focused trials with a greater chance of success
Allowing us to develop more drugs and deliver more options to patients
We design novel, high-quality trials, utilising our Scientific Affairs Group, an omic's-driven approach and an appreciation of regulatory pathways
Our in-house drug development team drives patient recruitment strategies, helping to achieve efficiencies, and protect against value erosion
We embed our specialist trial managers into the trial interface to have a direct representative between the CRO and trial centre
Our operations are entirely scalable to grow alongside the acquisition of new assets and to ensure we can always run clinical trials simultaneously
Our Scientific Affairs Group supplies our trial team with continued insight throughout the clinical development process, determining how best to develop treatments
We are at the forefront of innovative clinical studies, using multiple different types of novel trials to optimise success
We design novel, high-quality trials, utilising our Scientific Affairs Group, an omic's-driven approach and an appreciation of regulatory pathways
Our in-house drug development team drives patient recruitment strategies, helping to achieve efficiencies, and protect against value erosion
Right trial
We embed our specialist trial managers into the trial interface to have a direct representative between the CRO and trial centre
Right time
Our operations are entirely scalable to grow alongside the acquisition of new assets and to ensure we can always run clinical trials simultaneously
Right patient
Our Scientific Affairs Group supplies our trial team with continued insight throughout the clinical development process, determining how best to develop treatments
Accelerated trial completion and lower development costs can realise earlier benefit for both pharmaceutical partners and patients
We capitalise for the company as a whole, not a single trial so that in-licensed assets are allocated funding as soon as they need it, rather than having to wait for the capital from specific fundraising rounds
Quicker trial completion
Lower cost of development
Increased value of treatments
Faster route to market
Earlier benefit to patients
Accelerated trial completion and lower development costs can realise earlier benefit for both pharmaceutical partners and patients
Our rapidly extensible portfolio transforms our potential to improve the lives of patients
We accelerate development
We have a strong pipeline of clinical opportunities and we can scale globally
Our model vs traditional modelWe capitalise for the company as a whole, not a single trial so that in‑licensed assets are allocated funding as soon as they need it, rather than having to wait for the capital from specific fundraising rounds
Watch videoWe save more lives
Quicker trial completion
Lower cost of development
Increased value of treatments
Faster route to market
Earlier benefit to patients